The emerging therapeutic efficacy of ketamine and classical psychedelics for depression
has inspired tremendous interest in the underlying neurobiological mechanisms. We review …

Ketamine has emerged as a transformative and mechanistically novel pharmacotherapy for
depression. Its rapid onset of action, efficacy for treatment-resistant symptoms, and …

The mechanisms underlying the pathophysiology and treatment of depression and stress-
related disorders remain unclear, but studies in depressed patients and rodent models are …

Anhedonia is considered a core feature of major depressive disorder, and the dopamine
system plays a pivotal role in the hedonic deficits described in this disorder. Dopaminergic …

A single subanesthetic dose of ketamine, an NMDA receptor (NMDAR) antagonist, produces
rapid and sustained antidepressant actions in depressed patients, addressing a major …

Most currently available antidepressants target monoamine neurotransmitter function.
However, a purely neurotransmitter-based explanation for antidepressant drug action is …

Ketamine, an N-methyl-d-aspartate receptor (NMDAR) antagonist first developed as an
anesthetic, has shown significant promise as a medication with rapid antidepressant …

A hallmark of electrophysiological brain activity is its 1/f-like spectrum–power decreases with
increasing frequency. The steepness of this 'roll-off'is approximated by the spectral …

Abstract N-methyl-D-aspartate (NMDA) receptors mediate a slow component of excitatory
synaptic transmission, are widely distributed throughout the central nervous system, and …

The discovery of the antidepressant effects of ketamine has opened a breakthrough
opportunity to develop a truly novel class of safe, effective, and rapid-acting antidepressants …